LMCG Investments’s Alnylam Pharmaceuticals ALNY Stock Holding History

LMCG Investments’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-16,566	Closed	-$1.61M	–	538
2014 Q4	$1.61M	Sell	16,566 -32,665	-66%	-$3.03M	0.04%	360
2014 Q3	$3.85M	Sell	49,231 -10,757	-18%	-$694K	0.09%	290
2014 Q2	$3.79M	Buy	59,988 +34,290	+133%	+$2.04M	0.08%	298
2014 Q1	$1.73M	Buy	25,698 +15,194	+145%	+$1.18M	0.04%	343
2013 Q4	$675K	Buy	+10,504	New	+$627K	0.01%	404

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

LMCG Investments's ALNY Position: Q1 2015 in Review

LMCG Investments sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2015, closing a stake of 16,566 shares — an estimated $1.61M sold.

LMCG Investments first reported a position in ALNY in Q4 2013 and held it in 5 quarters. The position peaked at $3.85M in Q3 2014. 238 funds tracked by Wall St. Rank hold ALNY as of Q1 2015.

LMCG Investments reported no remaining Alnylam Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
LMCG Investments sold 16,566 Alnylam Pharmaceuticals shares in Q1 2015, an estimated $1.61M.
LMCG Investments first reported a position in Alnylam Pharmaceuticals in Q4 2013 and held it in 5 quarters.
LMCG Investments's Alnylam Pharmaceuticals position peaked at $3.85M in Q3 2014.
238 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2015.

Based on LMCG Investments's 13F filing for Q1 2015, filed 15 May 2015.